Form 4: NewAmsterdam Pharma Co N.V. Director James N. Topper Reports Share Purchase
SEC Form 4 Filing
Director James N. Topper reported the acquisition of 1,135 ordinary shares of NewAmsterdam Pharma Co N.V. at a weighted average price of $22.4851.
Summary
- On March 26, 2025, James N. Topper, a director of NewAmsterdam Pharma Co N.V., acquired 1,135 ordinary shares.
- The shares were purchased at a weighted average price of $22.4851, with prices ranging from $22.37 to $22.50.
- Following the transaction, Topper indirectly owns 3,013,569 shares through Frazier Life Sciences X, L.P. and 3,801,000 shares through Frazier Lifesciences Sponsor LLC.
- Topper disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider trading activity.
Key Dates
| Date | Description |
|---|---|
| 03/26/2025 | Date of transaction: James N. Topper acquired ordinary shares. |
| 03/28/2025 | Date of report: Form 4 filing date. |
Keywords
Form 4, Beneficial Ownership, James N. Topper, NewAmsterdam Pharma, Share Purchase, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.